Objectives: To report insidious development of autonomic dysreflexia and hydronephrosis due to dyssynergic voiding following discontinuation of intrathecal baclofen therapy. Setting: Regional Spinal ...

Intrathecal baclofen (ITB) therapy has evolved into a standard treatment for severe spasticity. After this therapy had been provided for 10 years, a retrospective chart review on 50 patients, ...

September 14, 2012 — The US Food and Drug Administration (FDA) has approved a new catheter (Ascenda, Medtronic Inc) for use in the delivery of intrathecal baclofen (ITB) therapy. According to the ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Today, CNS Therapeutics announced the FDA approval of Gablofen® (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a ...

Two traumatic brain-injury patients steadily emerged from minimally conscious state after receiving intrathecal baclofen therapy. At the International Neuromodulation Society's 11th World Congress, Dr ...

Researchers from Kessler Foundation and Kessler Institute for Rehabilitation (collectively "Kessler") conducted the first prospective study to assess whether transcutaneous spinal stimulation (TSS) ...

SISTERS is the first randomized, controlled, open-label, multicentre study to evaluate the efficacy and safety of ITB Therapy versus CMM with oral antispastic medications for treatment of PSS after ...

A 63-year-old patient bed ridden for nearly a year because of paralysis could finally feel the feet under his feet after undergoing intrathecal baclofen (ITB) therapy recently. KOLKATA: A 63-year-old ...

Mount Olive, New Jersey-based Flowonix Medical Inc. said Wednesday that the United States Food and Drug Administration granted approval to market the Prometra II Programmable Pump System for use with ...

Vancouver, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The global market for Intrathecal Baclofen (ITB) therapy systems reached a value of USD 1.11 Billion in the year 2022. According to the most recent ...